早期阶段18F-Flortaucipir tau-PET作为阿尔茨海默病脑代谢替代指标:与18F-FDG-PET及早期淀粉样蛋白-PET的比较
在日内瓦记忆中心评估的58名受试者中,于1年内接受双时相18F-Flortaucipir-PET早期采集(eTAU)和18F-FDG-PET,其中36名还接受双时相淀粉样蛋白-PET(eAMY)。eTAU与FDG及eAMY的SUVR均强正相关(r=0.84和r>0.87,p<0.001);eTAU和FDG均能区分A+/T+与A-/T-个体(AUC eTAU=0.604,AUC FDG=0.748),FDG优于eTAU(p=0.04),eAMY与eTAU判别力相当。
要点
- eTAU与FDG SUVR强正相关(r=0.84,p<0.001),与eAMY SUVR也强正相关(r>0.87,p<0.001)。
- eTAU和FDG SUVR均能显著区分A+/T+与A-/T-个体,AUC分别为0.604和0.748,FDG优于eTAU(p=0.04)。
- eAMY与eTAU SUVR判别力相当;eTAU可提供与脑葡萄糖代谢和灌注密切相关的灌注信息,但作为神经退行性生物标志物不如FDG-PET准确。
核心结论
- 早期阶段18F-Flortaucipir-PET可提供与脑区域葡萄糖代谢及早期淀粉样蛋白-PET所测灌注密切相关的灌注信息。
- eTAU作为神经退行性生物标志物不如FDG-PET准确。
研究设计与样本
- 在日内瓦记忆中心评估的58名受试者接受双时相18F-Flortaucipir-PET早期采集(eTAU)和18F-FDG-PET,间隔在1年内。
- 其中36名参与者还接受双时相淀粉样蛋白-PET(eAMY)。
- 计算标准化摄取值比(SUVR)以评估eTAU与各自FDG-PET及eAMY扫描的相关性。
- 在个体水平视觉和半定量评估低代谢和低灌注图谱及其空间重叠。
- 进行受试者工作特征分析比较eTAU、FDG和eAMY SUVR在A-/T-与A+/T+参与者间的判别力。
主要发现
- eTAU与FDG SUVR之间呈强正相关(r=0.84,p<0.001)。
- eTAU与eAMY SUVR之间呈强正相关(r>0.87,p<0.001)。
- 在个体水平发现与低代谢拓扑对应良好的显著低灌注簇,独立于潜在的神经退行性模式。
- eTAU和FDG SUVR均显著区分A+/T+与A-/T-个体(AUC eTAU=0.604,AUC FDG=0.748),FDG表现优于eTAU(p=0.04)。
- eAMY与eTAU SUVR显示相当的判别力。
关键数值与推荐
- eTAU与FDG SUVR相关系数r=0.84(p<0.001)。
- eTAU与eAMY SUVR相关系数r>0.87(p<0.001)。
- 区分A+/T+与A-/T-的AUC:eTAU=0.604,FDG=0.748,FDG优于eTAU(p=0.04)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: As dual-phase amyloid-PET can evaluate amyloid (A) and neurodegeneration (N) with a single tracer injection, dual-phase tau-PET might be able to provide both tau (T) and N. Our study aims to assess the association of early-phase tau-PET scans and 18F-fluorodeoxyglucose (FDG) PET and their comparability in discriminating Alzheimer's disease (AD) patients and differentiating neurodegenerative patterns. METHODS: 58 subjects evaluated at the Geneva Memory Center underwent dual-phase 18F-Flortaucipir-PET with early-phase acquisition (eTAU) and 18F-FDG-PET within 1 year. A subsample of 36 participants also underwent dual-phase amyloid-PET (eAMY). Standardized uptake value ratios (SUVRs) were calculated to assess the correlation of eTAU and their respective 18F-FDG-PET and eAMY scans. Hypometabolism and hypoperfusion maps and their spatial overlap were also evaluated at the individual level visually and semiquantitatively. Receiver operating characteristic analyses were performed to compare the discriminative power of eTAU, FDG, and eAMY SUVR between A-/T- and A+/T + participants. RESULTS: Strong positive correlations were found between eTAU and FDG SUVRs (r = 0.84, p < 0.001) and eTAU and eAMY SUVRs (r > 0.87, p < 0.001). Clusters of significant hypoperfusion with good correspondence to hypometabolism topographies were found at the individual level, independently of the underlying neurodegenerative patterns. Both eTAU and FDG SUVRs significantly distinguished A+/T + from A-/T- individuals (AUCeTAU=0.604, AUCFDG=0.748) with FDG performing better than eTAU (p = 0.04). eAMY and eTAU SUVR showed comparable discriminative power. CONCLUSION: Early-phase 18F-Flortaucipir-PET can provide perfusion information closely related to brain regional glucose metabolism and perfusion measured by early-phase amyloid-PET, even if less accurate than FDG-PET as a biomarker for neurodegeneration.
引用
- Boccalini C, Peretti DE, Mathoux G, et al. Early-phase 18F-Flortaucipir tau-PET as a proxy of brain metabolism in Alzheimer's disease: a comparison with 18F-FDG-PET and early-phase amyloid-PET. Eur J Nucl Med Mol Imaging. 2025. PMID: 39849149. doi:10.1007/s00259-024-07063-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。